Combined Liquid Chromatography-mass Spectrometry and Next-generation DNA Sequencing Detection of Adulterants and Contaminants in Analgesic and Anti-inflammatory Herbal Medicines
- 15 Downloads
Methods for assessing the quality of herbal medicine preparations have advanced significantly in recent years in conjunction with increases in herbal medicine use and reports of adulteration and contamination.
This study examined the quality of analgesic and anti-inflammatory herbal medicine preparations available on the Australian market by detecting the presence of listed ingredients, adulterants and contaminants.
Forty-nine analgesic and anti-inflammatory herbal medicine preparations were randomly sourced from Australian capital cities. They were audited using a dual approach of liquid chromatography-mass spectrometry (LC–MS) combined with next-generation DNA sequencing. Once screened, a comparison of listed ingredients with verified ingredients was conducted to determine the accuracy of labelling, and the extent of adulteration and contamination.
Twenty-six of 49 (53%) herbal medicines were adulterated or contaminated with undeclared ingredients. LC–MS revealed the presence of pharmaceutical adulterants including atropine and ephedrine. DNA sequencing uncovered concerning levels of herbal substitution, adulteration and contamination, including the use of fillers (alfalfa, wheat and soy), as well as pharmacologically relevant species (Centella asiatica, Panax ginseng, Bupleurum and Passiflora). Pig/boar and bird DNA was found in some preparations, inferring substandard manufacturing practices. Of the 26 contaminated samples, 19 (73%) were manufactured in Australia, and 7 (27%) were imported from other countries (6 from China, 1 from New Zealand). In 23 of 49 (47%) herbal medicine samples, no biological ingredients were detected at all. These were predominantly pain and anti-inflammatory preparations such as glucosamine and eicosapentaenoic and docosahexaenoic acids found in krill and fish oils, so DNA would not be expected to survive the manufacturing process.
The high level of contamination and substitution of herbal medicine preparations sourced from Australian dispensaries supports the need for more stringent pharmacovigilance measures in Australia and abroad.
Compliance with Ethical Standards
This study was funded by the Australian National Health and Medical Research Council (NHMRC) (grant #1061329).
Conflict of interest
Claire L. Hoban, Ian F. Musgrave, Roger W. Byard, Christine Nash, Rachael Farrington, Garth Maker, Elly Crighton, Michael Bunce, and Megan Coghlan report no known conflicts of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Therapeutic Goods Administration 2013. An Overview of the Regulation of Complementary Medicines in Australia. https://www.tga.gov.au/overview-regulation-complementary-medicines-australia. Accessed 7 Oct 2019.
- 4.von Conrady DM, Bonney A. Patterns of complementary and alternative medicine use and health literacy in general practice patients in urban and regional Australia. Skin. 2017;46(5):316–20.Google Scholar
- 6.Crighton E, Coghlan ML, Farrington R, Hoban CL, Power MWP, Nash C, Mullaney I, Byard RW, Trengove R, Musgrave IF, Bunce M, Maker G. Toxicological screening and DNA sequencing detects contamination and adulteration in regulated herbal medicines and supplements for diet, weight loss and cardiovascular health. J Pharm Biomed Anal. 2019;176:112834.PubMedCrossRefGoogle Scholar
- 7.Hoban CL, Musgrave IF, Coghlan ML, Power MW, Byard RW, Nash C, Farrington R, Maker G, Crighton E, Trengive R, Bunce M. Adulterants and contaminants in psychotropic herbal medicines detected with mass spectrometry and next-generation DNA sequencing. Pharm Med. 2018;32(6):429–44.CrossRefGoogle Scholar
- 8.Coghlan ML, Haile J, Houston J, Murray DC, White NE, Moolhuijzen P, Bellgard MI, Bunce M. Deep sequencing of plant and animal DNA contained within Traditional Chinese Medicines reveals legality issues and health safety concerns. PLoS Genet. 2012;8(4):e1002657. https://doi.org/10.1371/journal.pgen.1002657.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Coghlan ML, Maker G, Crighton E, Haile J, Murray DC, White NE, Byard RW, Bellgard M, Mullaney I, Trengove R, Allcock RJ, Nash C, Hoban C, Jarrett K, Edwards R, Musgrave IF, Bunce M. Combined DNA, toxicological and heavy metal analyses provides an auditing toolkit to improve pharmacovigilance of traditional Chinese medicine (TCM). Sci Rep. 2015;10:17475.CrossRefGoogle Scholar
- 28.Arbo MD, Larentis ER, Linck VM, Aboy AL, Pimentel AL, Henriques AT, Dallegrave E, Garcia SC, Leal MB, Limberger RP. Concentrations of p-synephrine in fruits and leaves of Citrus species (Rutaceae) and the acute toxicity testing of Citrus aurantium extract and p-synephrine. Food Chem Toxicol. 2008;46:2770–5.PubMedCrossRefPubMedCentralGoogle Scholar
- 37.Seethapathy GS, Raclariu-Manolica AC, Anmarkrud JA, Wangensteen H, de Boer HJ. DNA metabarcoding authentication of ayurvedic herbal products on the European market raises concerns of quality and fidelity. Front Plant Sci. 2019. https://doi.org/10.3389/fpls.2019.00068.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Real A, Comino I, de Lorenzo L, Merchán F, Gil-Humanes J, Giménez MJ, López-Casado MÁ, Torres MI, Cebolla Á, Sousa C, Barro F, Pistón F. Molecular and immunological characterization of gluten proteins isolated from oat cultivars that differ in toxicity for celiac disease. PLoS One. 2012;7:e48365.PubMedPubMedCentralCrossRefGoogle Scholar
- 42.FDA Poisonous Plant Database; Beath OA, Gilbert CS, Eppson HF, Rosenfeld I. Poisonous plants and livestock poisoning. Wyoming Agric Exp Sta Bull, 1953;324, 94. https://www.accessdata.fda.gov/scripts/plantox/detail.cfm?id=2851. Accessed 20 Feb 17.
- 43.Convention on International Trade in Endangered Species of Flora and Fauna, The CITES Appendices, available https://www.cites.org/eng/app/index.php. Accessed June 2017.
- 44.Therapeutic Goods Administration, Australian Regulatory Guidelines, Good Manufacturing Practice (GMP) Clearance for Overseas Manufacturers, 17th Edition, Version 1.0 May 2011. https://www.tga.gov.au/publication/manufacturing-principles-medicinal-products. Accessed 22 June 17.